Retroperitoneal Fibrosis and Ergot Derivatives

Stecker, John F.; Rawls, Harvey P.; Devine, Charles J.; Devine, Patrick C.

doi:10.1016/s0022-5347(17)59635-4

Cited by 43 publications

(24 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Perhaps some previously diagnosed cases of lymphocytic hypophysitis might have actually been intrasellar fibrosis associated with MFS. The etiology of most cases of RPFis unclear although drug administration (13) or autoimmune disease may be involved (14). Idiopathic RPF is usually associated with severe atherosclerotic plaques of the aortic wall.…”

Section: Discussionmentioning

confidence: 99%

Multifocal Fibrosclerosis: Retroperitoneal Fibrosis Associated with a Suprasellar Tumor and Pachymeningitis

et al. 2003

View full text Add to dashboard Cite

A 42 year-old man with lumbago and fever had hydronephrosis due to a mass surrounding the abdominal aorta, associated with pachymeningitis and a suprasellar tumor. He was given a diagnosis of multifocal fibrosclerosis, involving both retroperitoneal and intracranial fibrosis. He responded to treatment with corticosteroid and cyclophosphamide. The intracranial lesions seemed to be rare, but important manifestations of the systemic disease, and were clearly visualized by magnetic resonance imaging. The phenotype of the infiltrated lymphocytes was CD4+, supporting the hypothesis that autoimmunity was involved pathogenetically. We propose a comprehensive category termed "inflammatory fibrotic disease" including both systemic and localized diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Multifocal Fibrosclerosis: Retroperitoneal Fibrosis Associated with a Suprasellar Tumor and Pachymeningitis

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Patients with 10 to 14 days per month were considered to be in a critical state with an odds ratio of 20. 1 When patients have 5 to 9 headache days per month, I counsel the aforementioned with the exception that I strongly encourage "patient-centered" options such as Petadolex, magnesium, vitamin B2, or coenzymeQ10. I introduce the idea of use of conventional prevention and encourage but do not require its use when disability is as prior mentioned.…”

Section: June 2007mentioning

confidence: 99%

“…What is disputed is whether cortical spreading depression is a necessary phenomenon for triggering migraine, or for explaining the migraine pain, not if it happens without aura! 1 The objective of this study was to determine predictors of onset of new headache episodes and recovery from headache over 1 year. A population-based cohort study was conducted, comprising a baseline postal survey to a random sample of adults aged ≥18 years, with follow-up survey after 1 year.…”

Section: -Stewart J Tepper MDmentioning

confidence: 99%

“…I think the menstrual migraine short-term prevention treatments should not count as part of the acute medication 9-day limit, and there is no evidence that short-term prevention is associated with a rebound effect. 1 In addition, I believe that scheduled daily use of triptans is often well tolerated without development of medication overuse headache, and that one of the peculiar triggers to medication overuse headache, as suggested to me by Dr. Randy Weeks, may be pain contingent use of acute medications, rather than scheduled use as is done in short-term and long-term preventive treatment. 2 Objectives: (1) To reassess the prevalence of migraine in the United States; (2) to assess patterns of migraine treatment in the population; and (3) to contrast current patterns of preventive treatment use with recommendations for use from an expert headache panel.…”

mentioning

confidence: 98%

“…For this paradigm, 4 triptans have evidence of effectiveness, suggesting that triptan short-term prevention for menstrual migraine is a class effect, [1][2][3][4][5][6] as is triptan acute treatment for menstrual migraine. 1 Triptan short-term prevention must be evaluated with consideration of total monthly acute triptan requirements and limits. Caution about acute medication overuse needs not be stated to dedicated headache medicine specialists, but to the occasional reader this reminder can probably never be overstated.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Abstracts and Citations

Tepper¹,

Bigal²,

Taylor³

2007

Headache: The Journal of Head and Face Pain

View full text Add to dashboard Cite

PRIMARY HEADACHES Bennetto L, Patel NK, Fuller G. Trigeminal neuralgia and its management. BMJ. 2007;334:201-205.Trigeminal neuralgia is a severe unilateral paroxysmal facial pain, often described by patients as the "the world's worst pain." Data sources and selection criteria. We searched Medline, National Institute for Health and Clinical Excellence (NICE), and Cochrane databases using the terms "trigeminal neuralgia," "tic douloureux," and "facial pain." All related articles from the NICE and Cochrane databases were obtained. We searched Medline citation lists by title and abstract for relevant publications, including randomized control trials and review articles. The citation lists of these articles were hand searched for further relevant articles.Comment: This is a superb review with up-to-date information and graphics, published in a recent issue of the BMJ, and I recommend it.-Stewart J. Tepper, MD MIGRAINE: TREATMENT Tuchman M, Hee A, Emeribe U, Silberstein S. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs. 2006;20:1019-1026.Objective: To determine the efficacy and tolerability of zolmitriptan 2.5 mg oral tablet as an acute treatment for menstrual migraine attacks.Methods: This was a 2-phase, multicenter, randomized, double-blind, placebo-controlled, parallel-group outpatient study (Phase I is reported here). The study was conducted at 27 sites in the USA. Eligible women were randomized (1:1) to receive either zolmitriptan 2.5 mg oral tablet or placebo, and instructed to acutely treat up to 2 menstrual migraine attacks per menstrual period for up to 3 menstrual cycles with a single dose of study medication. Menstrual migraine was operationally defined as an attack occurring within the time period of 2 days prior to the expected onset of menses to 5 days after the onset of menses. Participants were asked to treat migraine headaches of moderate or severe intensity only that occurred >24 hours after the end of the last migraine attack and that had not been acutely treated with other medications. Information regarding each migraine attack was recorded by patients in treatment diary cards. The primary efficacy variable was 2-hour headache response (defined as a 2-point drop on a 4-point scale) for all attacks treated. Secondary variables included 1-and 4-hour headache response rate; 1-, 2-, and 4-hour headache response based on a 100-mm visual analogue scale (VAS); pain-free rate at 1, 2, and 4 hours; use of escape medication; the proportion of patients with recurrence within 24 hours of initial treatment; and tolerability.Results: The intention-to-treat population comprised 334 patients (zolmitriptan [n = 174]; placebo [n = 160]). Patients treated 625 attacks with zolmitriptan and 529 attacks with placebo. Twice as many patients who took zolmitriptan achieved a 2-hour headache response compared with placebo recipients (65.7% vs 32.8%; P < .0001). Furthermore, a significantly higher headache response was observed with zolmitriptan than placebo at a...

show abstract

Lower Extremity Arterial Insufficiency After Long-term Methysergide Maleate Therapy

Apesos¹,

Folse²

1979

Arch Surg

View full text Add to dashboard Cite

Retroperitoneal Fibrosis and Ergot Derivatives

Cited by 43 publications

References 16 publications

Multifocal Fibrosclerosis: Retroperitoneal Fibrosis Associated with a Suprasellar Tumor and Pachymeningitis

Multifocal Fibrosclerosis: Retroperitoneal Fibrosis Associated with a Suprasellar Tumor and Pachymeningitis

Abstracts and Citations

Lower Extremity Arterial Insufficiency After Long-term Methysergide Maleate Therapy

Contact Info

Product

Resources

About